Evidence map›Paper›PMID 32556493›Full record

ArticleInternational journal of legal medicine2021

Usefulness of a blood glucose and ketone monitoring device as a screening tool for lethal diabetic ketoacidosis.

Pierre-Antoine Peyron, Maëlle Plawecki, Maisy Lossois, Manuela Lotierzo, Eric Baccino, Jean-Paul Cristol

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of legal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Pierre-Antoine Peyron *Department of Forensic Medicine, University Hospital of Montpellier, Montpellier, France. pa-peyron@chu-montpellier.fr.ORCID http://orcid.org/0000-0003-1147-7181
Maëlle Plawecki *Department of Biochemistry, University Hospital of Montpellier, Montpellier, France.
Maisy LossoisDepartment of Forensic Medicine, University Hospital of Montpellier, Montpellier, France.
Manuela LotierzoDepartment of Biochemistry, University Hospital of Montpellier, Montpellier, France.
Eric BaccinoDepartment of Forensic Medicine, University Hospital of Montpellier, Montpellier, France.
Jean-Paul CristolDepartment of Biochemistry, University Hospital of Montpellier, Montpellier, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic ketoacidosis (DKA) is a frequent and life-threatening complication, whose diagnosis remains challenging in forensic practice. We aimed at assessing the performance of a commercially available blood glucose and ketone monitoring device (BGMD) in measuring glucose and ketone levels in post-mortem vitreous (VH) and blood samples, in order to determine if such a device can be used for screening lethal cases of DKA at autopsy. VH and blood samples were collected in cases of unexplained causes of death at autopsy. Glucose and β-hydroxybutyrate (BHB) were measured in VH and BHB in blood using the BGMD. The values were compared to those obtained with validated enzymatic methods. Values ≥ 10 mmol/L were considered to be elevated for glucose, and BHB values ≥ 2.5 mmol/L were considered to indicate ketoacidosis. There was a strong and significant correlation between VH glucose and blood BHB concentrations measured with the BGMD and the validated method (r = 0.78 and r = 0.80, p < 0.0001, respectively), whereas no correlation was found for VH BHB values (r = 0.19, p = 0.19). The sensitivity and specificity of the BGMD were both excellent (1.0) to detect elevated VH glucose levels with a threshold of 14.4 mmol/L, and to detect elevated blood BHB levels with a threshold of 2.85 mmol/L. In contrast, the specificity of the BGMD to detect high BHB levels in VH was poor (0.50) with an optimal threshold of 2.5 mmol/L. We showed that a commercially available BGMD is suitable for identifying cases of lethal DKA and other metabolic disorders at autopsy, through the investigation of vitreous glucose and blood BHB. We therefore recommend the systematic use of a BGMD for screening these conditions in cases of unexplained deaths.

Indexed as

3-Hydroxybutyric AcidBlood GlucoseBlood Glucose Self-MonitoringDiabetic KetoacidosisFemaleHumansKetonesMaleMiddle AgedSensitivity and SpecificityVitreous Body3-Hydroxybutyric AcidBlood GlucoseKetonesAutopsyBlood glucose monitoring deviceDiabetic ketoacidosisForensic pathologyPost-mortem biochemistryScreening

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.